Boehringer In­gel­heim inks deal for So­sei’s GPR52-tar­get­ing schiz­o­phre­nia port­fo­lio

Boehringer In­gel­heim is team­ing up with So­sei Hep­tares to ad­vance drug can­di­dates with the po­ten­tial to treat all three as­pects of schiz­o­phre­nia in a deal that in­cludes €25 mil­lion ($27.3 mil­lion) up­front.

Boehringer will get an ex­clu­sive op­tion to li­cense So­sei’s col­lec­tion of GPR52 ag­o­nists, in­clud­ing its first-in-class pro­gram, HTL0048149. So­sei could re­ceive a €60 mil­lion ($65.6 mil­lion) op­tion ex­er­cise pay­ment and up to €670 mil­lion ($732.9 mil­lion) in mile­stones plus tiered roy­al­ties, per a com­pa­ny re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER